Dendreon Corp
featured
Take a look at some of Friday's midday movers:
» Read MoreMore
-
NEW YORK, May 9- Three long-time favorites of the short-selling crowd are making those investors eat crow, as Tesla, Barnes& Noble and Green Mountain Coffee are racking up big gains, making an already painful year for contrarian investors even worse. Barnes& Noble shares rose 24 percent on reports of a possible acquisition of some of its assets by Microsoft.
-
SEATTLE-- Dendreon Corp. said Thursday that sales of its prostate cancer therapy Provenge fell in the first quarter because of increased competition from two newer drugs. Net revenue from Provenge fell 18 percent to $67.6 million, Dendreon said. Dendreon said it lost $72 million, or 48 cents per share, in the three months ended March 31.
-
*Risks include high valuation, competitive threats By Ransdell Pierson. TARRYTOWN, N.Y., May 7- Just two years ago, Regeneron Pharmaceuticals was a relatively obscure biotech company in the village of Tarrytown, a picturesque New York suburb better known for "Rip Van Winkle," "The Legend of Sleepy Hollow," and other creations of hometown author Washington Irving.
-
*Shares jump five-fold in two years, market value $26 bln. TARRYTOWN, N.Y., May 7- Just two years ago, Regeneron Pharmaceuticals was a relatively obscure biotech company in the village of Tarrytown, a picturesque New York suburb better known for "Rip Van Winkle," "The Legend of Sleepy Hollow," and other creations of hometown author Washington Irving.
-
March 6- Wall Street analysts aren't known to apologize for giving bad advice on stocks, much less admit they've made the worst call of their entire careers.
-
Feb 25- Dendreon Corp reported a smaller-than-expected quarterly loss versus a year-ago profit on Monday as revenue fell and restructuring costs weighed on the biotechnology company. In the fourth quarter, the maker of cancer treatments had a loss of $38.7 million, or 26 cents per share, compared with a year-ago profit of $38.1 million, or 26 cents per share.
-
Feb 25- Dendreon Corp reported a quarterly loss versus a year-ago profit on Monday as revenue fell and restructuring costs weighed on the biotechnology company. The fourth-quarter loss was $38.7 million, or 26 cents per share, compared with a profit of $38.1 million, or 26 cents per share. Excluding items, the loss was 26 cents per share.
-
*Wells Fargo net interest margin drops, shares slip. "It's a market that is waiting for more of a catalyst from earnings," said Quincy Krosby, market strategist at Prudential Financial in Newark, New Jersey. The S&P 500 has gained 5 percent over the last two weeks to take the benchmark to five-year highs.
-
*Wells Fargo net interest margin drops, profit jumps. NEW YORK, Jan 11- U.S. stocks edged lower on Friday after Wells Fargo& Co, the first major bank to kick off fourth-quarter earnings season for the financial sector, reported a decline in net interest margin despite a record profit in the latest quarter.
-
*Wells Fargo shares drop despite record profit. *Boeing falls as Dreamliner hit by two more incidents. NEW YORK, Jan 11- U.S. stocks dipped on Friday after a record profit at Wells Fargo failed to attract buyers and Boeing shares were pressured by two further problems with its new Dreamliner aircraft.
-
*Wells Fargo shares drop despite record profit. *Boeing falls as Dreamliner hit by two more incidents. NEW YORK, Jan 11- U.S. stocks dipped on Friday after a record profit at Wells Fargo failed to attract buyers and Boeing shares were pressured by two further problems with its new Dreamliner aircraft.
-
*Wells Fargo shares off, posts record profit. NEW YORK, Jan 11- U.S. stocks were set to firm at the open on Friday after the S&P 500 climbed to a five-year high a day earlier, as record profit from Wells Fargo failed to excite investors who awaited fresh trading incentives.
-
*Wells Fargo net interest margin drops, profit jumps. NEW YORK, Jan 11- U.S. stocks dipped on Friday, weighed by losses in the banking sector, after Wells Fargo& Co reported a decline in net interest margin despite a record profit in the latest quarter.
